Abstract #2244
Glycine is a potential biomarker for malignant transformation in brain tumors
Changho Choi 1 , Sandeep Ganji 1 , Zhongxu An 1 , Dianne Mendelsohn 1 , Marco Pinho 1 , Edward Pan 1 , Kevin Choe 1 , and Elizabeth Maher 1
1
University of Texas Southwestern Medical
Center, Dallas, Texas, United States
We report Gly elevation in brain tumors. Gly was
measured, with PRESS TE=97ms at 3T, in five subjects
with gliomas in vivo. In a WHO grade 3 oligodendroglioma
patient, the Gly level was substantially higher in the
tumor than in the contralateral. In three patients with
glioblastomas, Gly was elevated by 10 fold or more. A
longitudinal study in an oligoastrocytoma patient
indicated that Gly increases with tumor progression. Our
data suggest that Gly may be not only a useful biomarker
for evaluating the tumor malignancy but also a
noninvasive tool for monitoring the malignant
transformation.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Click here for more information on becoming a member.
